PF-06763809

PF-06763809 is a potent and selective inverse agonist of the nuclear receptor subfamily 1 group F member 3 (RORC2, also known as ROR gamma t), developed by Pfizer in collaboration with Karo Pharma for the treatment of chronic plaque psoriasis. The drug was designed to inhibit IL-17A production in T-helper 17 (Th17) cells, thereby reducing inflammation associated with psoriasis. It was formulated as a topical agent and demonstrated inhibition of IL-17A production in preclinical models. However, clinical studies showed that while it was well tolerated and had an acceptable safety profile, it did not significantly reduce skin infiltrate thickness or disease biomarkers compared to placebo. Development for plaque psoriasis has been discontinued[1][2][4][7].